Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 2162-2165, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, M.
Right arrow Articles by Horiuchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, M.
Right arrow Articles by Horiuchi, K.

Clinical Chemistry, Vol 39, 2162-2165, Copyright © 1993 by American Association for Clinical Chemistry

Quantification of the cross-link pentosidine in serum from normal and uremic subjects

M Takahashi, K Kushida, K Kawana, C Ishihara, M Denda, T Inoue and K Horiuchi
Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.

Pentosidine is a fluorescent cross-link compound that accumulates in human tissues from uremic and diabetic patients. Using SP-Sephadex C-25 pretreatment before reversed-phase HPLC, we developed a method for quantifying pentosidine in the acid hydrolysate of serum. We examined concentrations of pentosidine in serum from 98 patients with end-stage renal disease requiring hemodialysis and from 33 normal control subjects. The mean (+/- SD) concentration of pentosidine was significantly greater in serum from uremic patients than that from control subjects (1267 +/- 695 nmol/L vs 77 +/- 40 nmol/L, P = 0.0001). There was a significant correlation between serum pentosidine concentrations and age in control subjects (r = 0.453, P < 0.01), but not in uremic patients. Serum pentosidine significantly increased with the duration of hemodialysis treatment (r = 0.272, P < 0.05). The greater pentosidine concentrations in uremic patients may be caused by the increased synthesis of pentosidine (perhaps because of the retention of pentosidine precursors), by the retention of pentosidine molecule itself in end-stage renal failure, or both.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
M. Takahashi, M. Oikawa, and A. Nagano
Effect of Age and Menopause on Serum Concentrations of Pentosidine, an Advanced Glycation End Product
J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2000; 55(3): 137M - 140.
[Abstract] [Full Text]

Home page
 Rheumatology (Oxford)Home page
J. R. Chen, M. Takahashi, M. Suzuki, K. Kushida, S. Miyamoto, and T. Inoue
Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis
Rheumatology, December 1, 1999; 38(12): 1275 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. Rodriguez-Garcia, J. R. Requena, and S. Rodriguez-Segade
Increased concentrations of serum pentosidine in rheumatoid arthritis
Clin. Chem., February 1, 1998; 44(2): 250 - 255.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.